Patient leaflet - Equilis Prequenza
B. PACKAGE LEAFLET
PACKAGE LEAFLET:
Equilis Prequenza suspension for injection for horses
-
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Intervet International B.V.
Wim de Korverstraat 35
5831 AN Boxmeer
The Netherlands
-
2. NAME OF THE VETERINARY MEDICINAL PRODUCT
Equilis Prequenza suspension for injection for horses
-
3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
Each dose of 1 ml contains:
Active substances:
Equine influenza virus strains:
| A/equine-2/ South Africa/4/03 A/equine-2/ Newmarket/2/93 | 50 AU1 50 AU |
1Antigenic ELISA units
Adjuvant:
Iscom-Matrix containing:
| Purified saponin Cholesterol Phosphatidylcholine | 375 micrograms 125 micrograms 62.5 micrograms |
Clear opalescent suspension.
-
4. INDICATION(S)
Active immunisation of horses from 6 months of age against equine influenza to reduce clinical signs and virus excretion after infection.
Influenza
Onset of immunity: 2 weeks after the primary vaccination course
Duration of immunity: 5 months after the primary vaccination course
12 months after the first revaccination
-
5. CONTRAINDICATIONS
None.
-
6. ADVERSE REACTIONS
A diffuse hard or soft swelling (max. diameter 5 cm) may rarely occur at the injection site, regressing within 2 days. Pain at the injection site can occur in rare cases, which may result in temporary functional discomfort (stiffness). A local reaction exceeding 5 cm and possibly persisting longer than 2 days may occur in very rare cases. Fever, sometimes accompanied by lethargy and inappetence, may in very rare cases occur for 1 day, and up to 3 days in exceptional circumstances.
The frequency of adverse reactions is defined using the following convention:
-
– very common (more than 1 in 10 animals treated displaying adverse reaction(s))
-
– common (more than 1 but less than 10 animals in 100 animals treated)
-
– uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
-
– rare (more than 1 but less than 10 animals in 10,000 animals treated)
-
– very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
-
7. TARGET SPECIES
Horses
-
8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
-
1 ml. Intramuscular use.
Vaccination schedule :
Primary vaccination course
Administer one dose (1 ml) strictly intramuscularly, according to the following schedule:
- Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later.
Revaccination
It is recommended that a single booster dose should only be administered to horses that have already received a primary vaccination course using vaccines that contain the same types of equine influenza virus included in this vaccine. A primary vaccination course may be considered necessary in horses that have not been suitably primed.
The first revaccination (third dose) is given 5 months after the primary vaccination course. This revaccination results in immunity to equine influenza lasting at least 12 months.
The second revaccination is given 12 months after the first revaccination.
The alternate use, at 12 months interval, of a suitable vaccine against equine influenza, containing the strains, A/equine-2/South Africa/4/03 and A/equine-2/Newmarket-2/93, is recommended to maintain immunity levels for the influenza component (see scheme).
| VI | V2 5 | V3 | 12 | V4 | 12 | V5 |
| 0 | 1 | 6 | 18 | 30 months | ||
| Scheme 1 | ||||||
| Pœquenza | Pre que 112a | PrequeiEa | PrequeiEa- | PrequeiEa | ||
| Te | Te | Te | ||||
| Scheme 2 | ||||||
| PiequeiEa | PrequeiEa | Pre que 112a | PrequeiEa | PrequeiEa |
In case of increased infection risk or insufficient colostrum intake, an additional initial injection can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 6 months of age and 4 weeks later).
-
9. ADVICE ON CORRECT ADMINISTRATION
Allow the vaccine to reach room temperature before use.
-
10. WITHDRAWAL PERIOD(S)
Zero days.
-
11. SPECIAL STORAGE PRECAUTIONS
Keep out of the sight and reach of children.
Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protected from light.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.
-
12. SPECIAL WARNING(S)
Special warnings for each target species:
Foals should not be vaccinated before the age of 6 months, especially when born to mares that were revaccinated in the last two months of gestation, because of possible interference by maternally derived antibodies.
Vaccinate healthy animals only.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental self-injection, seek medical advice immediately and show this package insert or the label to the physician.
Pregnancy and lactation:
Can be used during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Overdose (symptoms, emergency procedures, antidotes):
Following the administration of a double dose of vaccine, no side-effects other than those described under section 6. Adverse reactions, have been observed except for some depression at the day of vaccination.
Incompatibilities:
Do not mix with any other veterinary medicinal product.
-
13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
-
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
<DD/MM/YYYY>
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency.
-
15. OTHER INFORMATION